One integration.
Two disease insights.

Ultromics' AI models are delivered through a single integrated workflow platform, supporting clinicians in identifying patients who may have HFpEF or cardiac amyloidosis.

Book a demo

arrow_forward

Explore clinical validation

arrow_forward

INTEGRATION

Automated insights, delivered through your existing workflow.

Ultromics' AI models analyze a standard apical four chamber view to detect HFpEF and screen for cardiac amyloidosis. AI findings are sent directly into existing clinical systems. No changes to how studies are acquired, interpreted, or reported.

AI ANALYSIS

From echo scan to disease insight, within minutes.

Routine echocardiography studies are securely routed through standard DICOM workflows and automatically analyzed by Ultromics' AI models. Findings are typically available within 20 minutes, supporting clinical review and patient assessment.

Echo studies are acquired and securely routed through standard DICOM workflows. No changes to scanning protocols or acquisition workflows are required. Compatible with existing ultrasound systems.

Echo studies are automatically analyzed by EchoGo® Heart Failure to detect patients who may have HFpEF, and by EchoGo® Amyloidosis to screen for cardiac amyloidosis. No manual interaction is required.

AI findings are returned directly into PACS and EMR systems, making results available where clinicians already work. AI findings are typically delivered in under 20 minutes to support clinician assessment.

"Healthcare providers are looking for solutions that are trusted, secure and simple to deploy that come fully managed with 24/7 support. Ultromics provides a secure solution”

David Houlding

Director of Healthcare Experiences, Microsoft.

CLINICAL FINDINGS

Built around the way echo teams already work

AI findings are returned directly into PACS, CVIS, and EMR systems, making results available alongside routine echocardiography studies. Clinicians can review AI findings within their existing workflow, without additional software or manual review steps.

Discover EchoGo® Heart Failure

Discover EchoGo® Amyloidosis

WORKFLOW IN ACTION

Ultromics within Fujifilm Synapse®

Ultromics AI for HFpEF detection and Cardiac Amyloidosis screening can be surfaced directly within Fujifilm Synapse®, allowing clinicians to access AI insights from within their existing reading environment. Studies continue through established workflows, with no additional logins, software, or workflow steps required.

Watch webinar

“We closely collaborate with our clients, thoroughly assessing their workflow needs to ensure seamless integration. Leveraging our integrations with PACS and EMR, we implement advanced filtration based on clinical indication or disease risk, seamlessly returning reports and streamlining billing processes."

Amir Hasan

Chief Operating Officer, Ultromics

SEAMLESS INTEGRATION

AI insights without workflow disruption.

AI findings are returned directly into existing clinical systems, allowing clinicians to review results alongside routine echocardiography studies, with no additional workflow steps, hardware, or scanning protocols required.